The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing of New Ordinary Shares

22 Mar 2011 07:00

RNS Number : 3574D
PuriCore Plc
22 March 2011
 



PuriCore plc

(the "Company")

Placing of New Ordinary Shares

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 22 March 2011 - PuriCore (LSE: PURI), the water-based clean technology company, is pleased to announce that it has raised £1.2 million by way of a Placing (the "Placing") of 2,272,727 new ordinary shares of 10 pence each ("Ordinary Shares") in the Company (the "Placing Shares").

 

The Placing has been completed at a price of 52.8 pence per Placing Share representing a premium of approximately 5.6% per cent. to the closing mid-market price per Ordinary Share on 21 March 2011.

 

The net proceeds of the Placing will be used to provide working capital to the Company, giving it additional financial flexibility and to facilitate growth.

 

Application has been made for the Placing Shares to be admitted to the Official List of the UK Listing Authority and to trading on the main market for listed securities of the London Stock Exchange Plc, respectively. Dealings in the Placing Shares are expected to commence at 8:00a.m. on 23 March 2011 ("Admission").

 

Commenting on the Placing, Chris Wightman, Executive Chairman, said:

 

"Today's placing provides PuriCore with additional working capital at a time of global uncertainty. It will enable us to continue to build sales and market share in our US food business where the advantages of our unique chemistry have been validated by many of the largest food retailers in the US and where we are now expanding into the floral industry. We believe that, with the new formulations now available to us, we have the potential to expand our technology quickly into new markets, including wound management and agriculture, and look forward to reporting progress when we deliver our final results."

 

 

Enquiries:

Financial Dynamics

Susan Quigley

Ben Brewerton

+44 (0) 20 7831 3113

PuriCore

Chris Wightman

Executive Chairman

+44 (0) 20 7290 3440

 

 

About PuriCore

PuriCore plc is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

 

Details of the Placing

The Company has raised £1.2 million (before expenses) by the issue of 2,272,727 Placing Shares. The Placing Shares represent approximately 9.09 per cent. of the enlarged share capital of the Company.

 

The Company has conditionally placed the Placing Shares with institutional and private investors at a price of 52.8 pence per share.

 

The Placing Price represents a premium of approximately 5.6 per cent. to the closing mid-market price of 50.0 pence per Ordinary Share on 21 March 2011, being the last dealing day prior to the release of this announcement. The Placing Shares will represent an increase of approximately 9.998 per cent. in the current issued share capital of the Company. Following Admission of the Placing Shares, the Company will have a total of 25,003,770 Ordinary Shares in issue.

 

It is anticipated that dealings in the Placing Shares will commence at 8:00 a.m. on 23 March 2011. The Placing is conditional, inter alia, upon Admission becoming effective no later than 8:00 a.m. on 23 March 2011 or such later date (being not later than 8.00 a.m. on 22 April 2011) as the Company shall determine.

 

The Placing Shares will be issued credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared or paid thereon following Admission.

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDKDDQNBKBANB
Date   Source Headline
9th Oct 20185:02 pmRNSForm 8.3 - Realm Therapeutics PLC
9th Oct 201810:13 amRNSForm 8.3 - Realm Therapeutics plc
5th Oct 20186:08 pmBUSForm 8.3 - Realm Therapeutics PLC
5th Oct 20182:00 pmRNSFORM 8.3 - Realm Therapeutics Plc
4th Oct 20188:57 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics plc
2nd Oct 201810:43 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics PLC
1st Oct 20187:00 amRNSProvides Update on Timing of Formal Sale Process
24th Sep 20189:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Sep 201811:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20183:16 pmRNSHolding(s) in Company
20th Sep 201811:53 amRNSForm 8.3 - REALM THERAPEUTICS PLC
20th Sep 201811:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Sep 20184:31 pmRNSForm 8 (OPD) - Realm Therapeutics plc
19th Sep 201811:11 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
18th Sep 201811:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Sep 20187:00 amRNSCorporate Update and Hiring of Advisor
20th Aug 201811:00 amRNSPrice Monitoring Extension
20th Aug 20187:00 amRNSBlock listing Interim Review
15th Aug 20184:35 pmRNSPrice Monitoring Extension
14th Aug 20187:10 amRNSHalf-year Report
8th Aug 20187:00 amRNSPresents at Wedbush PacGrow Healthcare Conference
7th Aug 20187:00 amRNSNotice of Results
16th Jul 20185:33 pmRNSHolding(s) in Company
10th Jul 20187:00 amRNSPre-Clinical Study in Atopic Dermatitis
4th Jul 20187:00 amRNSInstructions for Exchanging Ordinary Shares
4th Jul 20187:00 amRNSSEC registration effective NASDAQ listing approved
14th Jun 201810:54 amRNSResult of AGM
31st May 20187:00 amRNSRealm to Present at June Investor Conferences
24th May 20187:00 amRNSEnrollment complete for Phase 2 study of PR022
23rd May 20187:00 amRNSFiling with US SEC to Facilitate Nasdaq Listing
21st May 20187:00 amRNSData Presentation at IID 2018
2nd May 201812:39 pmRNSAnnual Financial Report Available
2nd May 20187:00 amRNSFinal Results
2nd May 20187:00 amRNSRealm Files Registration for Nasdaq Listing of ADS
26th Apr 20182:32 pmRNSNotice of Results
12th Mar 20184:40 pmRNSSecond Price Monitoring Extn
12th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Mar 20187:00 amRNSClinical Update including PR013 Phase II results
8th Mar 20187:00 amRNSPresenting at Cowen Healthcare Conference
27th Feb 20187:00 amRNSPatent portfolio strengthened with USPTO allowance
20th Feb 201812:00 pmRNSPresentation at RBC Healthcare Conference
16th Feb 20187:00 amRNSBlock listing Interim Review
15th Feb 20187:00 amRNSClinical and Business Update
2nd Jan 20187:00 amRNSPresents at 5th Annual Dermatology Summit
15th Dec 20177:00 amRNSDirector/PDMR Shareholding
12th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR013
5th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.